Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Reiterates Buy on INNOVENT BIO, Cuts TP to HKD124
Recommend 4 Positive 3 Negative 1 |
||||
|
||||
|
According to a UBS research report, INNOVENT BIO (01801.HK)'s 2H25 revenue grew by 29.6% YoY to RMB7.1 billion, in line with expectations, while net loss for the period reached RMB21 million, below the broker's and the market's expectations. For the entire year, INNOVENT BIO's 2025 revenue surged by 38.4% YoY to RMB13 billion. The company recorded net profit of RMB814 million, successfully turning from loss to profit. UBS has dropped its target price for INNOVENT BIO from HKD131.2 to HKD124 but reiterated the Buy rating, AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
